Partially funded by the WMFC and presented at ASH in December, 2022, this research identified three subtypes of WM.

The full abstract that Dr. Hunter presented at ASH is available here.

Two other WM-related abstracts using the multiomic analysis from Dr. Hunter’s research were also presented at ASH:

  • An in-depth investigation into why epigenomic regulation is so important to MYD88 mutations is available here
  • The data also has been applied to investigating why ibrutinib (and by extension other BTK inhibitors) may result in long Progression-Free Survival (PFS); that abstract is available here